Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 11, 2026Cancer Research CommunicationsOpen Access

Schlafen 11 (SLFN11) is overexpressed in multiple myeloma and undergoes nucleolar translocation in response to bortezomib

View Full Paper
Ask AI
Bookmark
Share

Authors

YAYasuhiro ArakawaDTDaiki TaniyamaKSKazuhito Suzuki

Discussion

Loading...

Member takes

Overview

Randomized trial reveals SLFN11's role in bortezomib response among multiple myeloma patients, indicating potential as a biomarker.

Key Points

  • This research investigates the role of SLFN11 in multiple myeloma (MM) and its impact on treatment response.
  • Analyzed SLFN11 expression using TCGA and MMRF CoMMpass datasets.
  • Assessed SLFN11 protein levels in bone marrow and cell line samples.
  • Utilized SLFN11-knockout MM cell lines to test sensitivity to bortezomib.
  • SLFN11 is highly expressed in multiple myeloma subtypes and correlates with transcriptional programs.
  • Bortezomib induces nucleolar translocation of SLFN11, suppressing ribosomal RNA synthesis.
  • Patients with low SLFN11 expression benefitted more from bortezomib therapy in the HOVON-65/GMMG-HD4 trial.

Cite This Study

Arakawa et al. (2026) studied this question.

synapsesocial.com/papers/6a51ddbfc18d7f28ca500152https://doi.org/10.1158/2767-9764.crc-26-0162
View Full Paper
Ask AI
Bookmark
Share